ASH News Daily 2016 - Issue 3 - A-14

American Society of Hematology
Self-Assessment Program
(ASH -SAP)
®

CONFERENCE
SPECIAL

10%
OFF

NEW! SIXTH EDITION
The Premier Self-Assessment
Program for Hematologists
The Sixth edition of ASH-SAP covers the full spectrum
of adult & pediatric hematology including benign and
malignant disorders.

23
285
6

ASH News Daily

Page A-14
®

Biology

«« From Page A-9

communities was a tremendous
success. The session's four talks,
featuring speakers from both scientific disciplines, highlighted promising techniques to alter cell signaling
and gene expression in hemoglobinopathies. These techniques took
decades of relentless work and collaboration between many different research groups. The speakers,
Drs. Ann Dean, Marina Cavazzana,
Harvey Lodish, and Lucia De Franceschi, skillfully represented the research diversity required to bring
these innovative therapies from
bench to bedside, with an emphasis on how the techniques can be
(and already have been) applied in
the clinical setting. "At the beginning, I doubt anyone was confident
these studies would yield anything
beyond fundamental knowledge of
transcription," mused Dr. Minella,
"yet we are now at a point where
these potentially curative methods
can be tested in patients."
The discussed erythrocyte reprogramming techniques included gene
therapy, gene editing, hemoglobin
transcription regulation, and stimulation of erythroid progenitors - all

methods aimed at correcting intrinsic biologic errors in chronic anemias, especially hemoglobinopathies.
By using a patient's endogenous
cells, these therapies have a distinct
advantage over bone marrow transplantation. Session co-chair Dr. Colleen Delaney stated that the session
represented "a major step forward in
the treatment of patients with hemoglobinopathies. Previously, stem cell
transplant was the only known cure,
but transplant carries with it a risk
for treatment-related mortality and
lifelong complications."
Longing to be at the cutting-edge,
but missed this electrifying session?
If so, don't miss the Presidential
Symposium tomorrow at 9:45 a.m.
in Hall AB of the San Diego Convention Center, where these groundbreaking therapies will be discussed
again, specifically in the context of
sickle cell disease.
Dr. Naik indicated no relevant conflicts of interest.
If you can dream it,
they can draw it.
Find us in the lobby
outside Hall A
#ASHunt

Pertinent chapters-7 with multimedia
featuring 3D animation & audio
New questions with multiple choice answers
Tests-earn up to 70 CME/MOC credits

SPECIAL CONFERENCE PRICES
Premier + CME/MOC

10% Off

Print and online Textbook, print Q & A Book,
and online CME/MOC exam
Member - Active and International

$490

$441

Member - U.S. & International Associate

$360

$324

Member - Graduate/Medical Student/
Resident

$250

$225

Non-member

$630

$567

Digital + CME/MOC
Online textbook and CME/MOC exam

10% Off

Member - Active and International

$380

$342

Member - U.S. & International Associate

$250

$225

Member - Graduate/Medical Student/
Resident

$150

$135

Non-member

$520

$468

hematology.org/BuyASHSAP6

The Leukemia &
Lymphoma Society
is leading the offensive
against acute myeloid
leukemia.
Beat AML is a groundbreaking Master Trial for
patients with acute myeloid leukemia (AML).
The Leukemia & Lymphoma Society (LLS) is leading a
multi-institutional collaborative clinical trial to increase
understanding of the underlying causes of AML and
develop more effective therapies to treat patients.

Enroll your newly
diagnosed AML patients
in a clinical trial today.

Contact an Information Specialist
800.955.4572 or visit www.lls.org/beat-aml
Thanks to the American Society of Hematology for its support in raising awareness and providing education about this critical initiative.

http://www.hematology.org/BuyASHSAP6

Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 3